Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Levodopa-carbidopa

Levodopa/Carbidopa (Sinemet ) Standard, immediate-release LD Sinemet CR Start with 1 tab (1 00 mg LD, 25 mg CD) two or three times daily ... [Pg.479]

The controlled-release (CR) formulation is more slowly absorbed and longer acting than immediate-release tablets. Patients need to increase the total daily dose by 30%, as it is not as bioavailable as the immediate-release levodopa/carbidopa. The CR formulation has a delayed onset (45 to 60 minutes) compared to the standard formulation (15 to 30 minutes). Thus, patients may also need to take immediate-release tablets or even a liquid formulation when they want a quicker onset of effect, such as with the first morning dose.1,8,25... [Pg.481]

Levodopa/carbidopa 1.5-2 100-200 Nausea/vomiting, high incidence... [Pg.629]

Shoptaw S., Watson D.W., Reiber C. et al. Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST). Addiction. 100(Suppl. 1) 78, 2005. [Pg.102]

The most important alternatives to levodopa therapy are direct-acting dopamine receptor agonists, such as ropinirole,pramipexole, or pergolide (Fig. 46-5). A number of studies have shown that use of these agents may help to delay the need for use of levodopa/carbidopa. This has... [Pg.769]

Dopamine-Boosting Medications. Levodopa/carbidopa (Sinemet), bromocriptine (Parlodel), pramipexole (Mirapex), and ropinirole (Requip) increase dopamine nenrotransmission in the brain by one or another mechanism. These medications do not reliably induce sleep, and in some patients are activating. They are certainly not true sedative-hypnotics. They are most often used by neurologists to treat Parkinson s disease. [Pg.272]

Patients currently treated with levodopa Levodopa must be discontinued at least 12 hours before therapy with levodopa/carbidopa. Substitute the combination drug at a dosage that will provide about 25% of the previous levodopa dosage. [Pg.1302]

Parkinson s disease As an adjunct to levodopa/carbidopa to treat patients with idiopathic Parkinson s disease who experience the signs and symptoms of end-of-dose wearing-off. The effectiveness of entacapone has not been systematically evaluated in patients with idiopathic Parkinson s disease who do not experience end-of-dose wearing-off. ... [Pg.1304]

The recommended dose of entacapone is one 200 mg tablet administered concomitantly with each levodopa/carbidopa dose to a maximum of 8 times/day (200 mg X 8 = 1600 mg/day). Clinical experience with daily doses greater than 1600 mg is limited. [Pg.1304]

Always administer entacapone in combination with levodopa/carbidopa. Entacapone has no antiparkinsonian effect of its own. [Pg.1304]

Entacapone can be combined with the immediate- and sustained-release formulations of levodopa/carbidopa. [Pg.1304]

Parkinson s disease Adjunct in the management of parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. [Pg.1310]

Parkinsonian patients receiving levodopa/carbidopa therapy who demonstrate a deteriorating response to this treatment 10 mg per day administered as divided doses of 5 mg each taken at breakfast and lunch. There is no evidence that additional benefit will be obtained from the administration of higher doses. [Pg.1310]

After 2 to 3 days of treatment, attempt to reduce the dose of levodopa/carbidopa. A reduction of 10% to 30% appears typical. Further reductions of levodopa/carbidopa may be possible during continued selegiline therapy. [Pg.1310]

Parkinson cf/sease Adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson disease. [Pg.1312]

Pergolide is usually administered in divided doses 3 times/day. During dosage titration, the dosage of concurrent levodopa/carbidopa may be cautiously decreased. In clinical studies, the mean therapeutic daily dosage of pergolide was 3 mg/day. [Pg.1312]

The average concurrent daily dosage of levodopa/carbidopa (expressed as levodopa) was approximately 650 mg/day. The efficacy of pergolide at doses above 5 mg/day has not been systematically evaluated. [Pg.1312]

WARNING Cases of fulminant liver failure resulting in death have occurred Uses Adjunct to carbidopa/levodopa in Parkinson Dz Action COMT inhibitor slows levodopa metabolism Dose 100 mg PO tid w/ 1st daily levodopa/carbidopa dose, then dose 6 12 h later -1- w/ renal impair Caution [C, ] Contra Hqjatic impair, w/ nonselective MAOI Disp Tabs SE Constipation, XCTOstomia, vivid dreams, hallucinations, anorexia, N/D, orthostasis, liver failure, Rhabdomyolysis Interactions T Effects OF CNS dqjressants, SSRIs, TCAs, warfarin, EtOH t risk of hypotensive crisis W/ nonselective MAOIs (phenelzine, tranylc5 promine) EMS Has been associated w/ liver failure and death may experience hallucinations concurrent EtOH use can T CNS dqjression T effects of warfarin severe D is common sevoal wks afto starting OD May cause NA and dizziness... [Pg.307]

With long term levodopa therapy the risk for the occurrence of on-off effects, periodically and paroxysmally occurring periods of the therapy becoming ineffective, increases. Decreasing the peak-trough fluctuations with slow-release levodopa/ carbidopa formulations could possibly diminish these on-off effects. [Pg.360]

The two COMT inhibitors in clinical use are tol-capone (Tasmar) and entacapone fComtan). They are used in combination with levodopa-carbidopa. In patients with motor fluctuations, they increase the on time. Adverse effects are similar to those observed with levodopa-carbidopa alone. Tolcapone therapy can cause fatal hepatotoxicity and so should be used only in patients who do not respond to other therapies. Patients taking tolcapone require close monitoring of liver enzymes for signs of hepatic changes. [Pg.370]

M. K. is a 60-year-old woman with Parkinson s disease. Her current therapy is levodopa-carbidopa. She complains that she frequently goes from being... [Pg.371]

Adjunct to levodopa/carbidopa in Parkinson s disease longer acting than bromocriptine... [Pg.962]


See other pages where Levodopa-carbidopa is mentioned: [Pg.266]    [Pg.266]    [Pg.267]    [Pg.267]    [Pg.478]    [Pg.478]    [Pg.481]    [Pg.482]    [Pg.628]    [Pg.22]    [Pg.98]    [Pg.342]    [Pg.364]    [Pg.147]    [Pg.249]    [Pg.369]    [Pg.371]    [Pg.372]    [Pg.372]    [Pg.372]    [Pg.373]    [Pg.619]    [Pg.471]    [Pg.605]   
See also in sourсe #XX -- [ Pg.272 ]




SEARCH



Carbidopa

Carbidopa, levodopa with

Levodopa

Levodopa/carbidopa adverse effects

Levodopa/carbidopa dosage

Levodopa/carbidopa in Parkinson’s disease

Levodopa/carbidopa liquid formulation

© 2024 chempedia.info